Genus Pharmaceuticals Ltd - Zoekresultaten

genus pharmaceuticals limited linthwaite, huddersfied hd7 5qh, united kingdom - mucopolysaccharide polysulfuric, acid ester, lauromacrogol - rectal ointment - mucopolysaccharide polysulfuric acid ester 0.2 % (w/w) lauromacrogol 400 5 % (w/w) - vasoprotectives

Verenigde Staten - Engels - NLM (National Library of Medicine)

lidocaine- lidocaine ointment

ingenus pharmaceuticals, llc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidocaine 50 mg in 1 g - lidocaine ointment 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. it is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type or to other components of lidocaine ointment 5%.

Verenigde Staten - Engels - NLM (National Library of Medicine)

allopurinol - allopurinol tablet

ingenus pharmaceuticals llc - allopurinol (unii: 63cz7gjn5i) (allopurinol - unii:63cz7gjn5i) - allopurinol 100 mg - this is not an innocuous drug. it is not recommended for the treatment of asymptomatic hyperuricemia. allopurinol tablets reduce serum and urinary uric acid concentrations. its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see clinical pharmacology, contraindications, warnings, and precautions). allopurinol tablets are indicated in: 1. the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2. the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. treatment with allopurinol tablets should be discontinued when the potential for overproduction of uric acid is no longer present. 3. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in m